In addition, the Pro12Ala polymorphism was regarded to change the response of synthetic PPARγ agonists– thiazolidinediones (TZDs) treatment [15], which seemed to improve the insulin resistance [16] and limit atherosclerosis development [17]. The gene discussed is PPARG; the disease is atherosclerosis.